PASylated exendin4 - XL-protein GmbH
Alternative Names: PAS-Exendin4; xl-110Latest Information Update: 28 Sep 2020
At a glance
- Originator XL-protein GmbH
- Class
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Diabetes mellitus
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Diabetes-mellitus in Germany
- 09 Aug 2016 PASylated exendin4 - XL-protein GmbH is available for licensing as of 09 Aug 2016. http://www.xl-protein.com/
- 09 Aug 2016 Preclinical trials in Diabetes mellitus in Germany (unspecified route)